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Abstract: Human Mesenchymal Stem Cells (hMSCs) have emerged in the last few years as one of the 
most promising therapeutic cell sources and, in particular, as an important tool for regenerative medi-
cine of skeletal tissues. Although they present a more restricted potency than Embryonic Stem (ES) 
cells, the use of hMCS in regenerative medicine avoids many of the drawbacks characteristic of ES 
cells or induced pluripotent stem cells. The challenge in using these cells lies into developing precise 
protocols for directing cellular differentiation to generate a specific cell lineage. In order to achieve 
this goal, it is of the upmost importance to be able to control de process of fate decision and lineage 
commitment. This process requires the coordinate regulation of different molecular layers at transcriptional, posttranscrip-
tional and translational levels. At the transcriptional level, switching on and off different sets of genes is achieved not only 
through transcriptional regulators, but also through their interplay with epigenetic modifiers. It is now well known that 
epigenetic changes take place in an orderly way through development and are critical in the determination of lineage-
specific differentiation. More importantly, alteration of these epigenetic changes would, in many cases, lead to disease 
generation and even tumour formation. Therefore, it is crucial to elucidate how epigenetic factors, through their interplay 
with transcriptional regulators, control lineage commitment in hMSCs. 
Keywords: Epigenetics, Bone, Osteoporosis, Mesenchymal stem cells, Histone acetylation, Histone methylation, DNA methy-
lation. 
1. INTRODUCTION 
 Mesenchymal stem cells (MSCs) are multipotent adult 
stem cells of mesodermal origin firstly characterized in 1970 
[1]. MSCs can be isolated from different adult tissues, in-
cluding bone marrow and adipose tissue [2-7]. Human MSCs 
(hMSCs) are thought to be one of the most useful cell 
sources for clinical application in tissue regeneration due to 
their ability to produce multiple cell types. Although hMSCs 
are normally in a quiescent state [8], in response to specific 
signals (i.e. tissue injury), they are capable of self-renewing 
to produce more hMSCs but also, of dividing asymmetrically 
producing lineage-committed progenitors that will differen-
tiate into the required cell types. Although initially it was 
thought that MSCs were only able to give rise to the cell 
types found in the tissue they were isolated from, we now 
know that hMSCs not only are able to differentiate in a vari-
ety of cell types of mesodermal germ layer, such as adipo-
cytes and osteocytes, but they can also differentiate into cells 
types of other germinal layers through a process known as 
“transdifferentiation” [5, 9-17] (Fig. 1). While hMSCs have 
a more restricted differentiation potential than embryonic 
stem (ES) cells, they show other great advantages. hMSCs 
can be easily sourced from adult tissues such as bone mar-
row, muscle and fat, and therefore, their use generally  
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implies a lower risk of immune rejection. Additionally, their 
ability to transdifferentiate helps to create a microenviron-
ment that favours tissue repair [18, 19]. In contrast to the 
known genomic instability of ES cells, there are few reports 
of oncogenic transformation in adult derived stem cells, and 
these cases are normally associated with long-term culture 
[20]. Moreover, the use of human MSCs is not subjected to 
the same ethical controversies as the use of human ES cells. 
Altogether, these unique characteristics have made of the 
MSCs the best candidates for cell therapy. 
 There are two different approaches for the application of 
hMSCs-based therapies in regenerative medicine. The first 
approach would consist in using these cells in their undiffer-
entiated state, allowing the differentiation to take place at the 
site where the damage needs to be repaired. The downside of 
this strategy is the possibility of the cells differentiating to-
wards cell types others than the required one at the repair 
site. To overcome this problem, a second approach is to dif-
ferentiate the cells in vitro prior to their transplantation [7]. 
Although his second approach seems to be more appropriate 
and would involve lower failure risks, it requires a successful 
in vitro differentiation prior implantation. Thus, in order to 
attain the required cell identity minimizing the risk of onco-
genic transformation we obviously require a deep under-
standing of all the regulatory mechanisms driving the differ-
entiation process in hMSCs. 
 Differentiation of stem cells requires the activation of 
genes involved in the developing of a specific cell type on 
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one hand and the suppression of specific sets of genes re-
sponsible for cell stemness on the other hand [21]. Since 
there are almost no difference between the coding sequences 
of MSCs and that of the specific cell types that they can give 
rise to, it seems clear that the differential gene expression 
that drives the appearance of different cell types is driven by 
epigenetic factors [22]. Epigenetic changes refer to reversi-
ble, heritable changes in gene regulation that occur without a 
change in DNA sequence. The more studied epigenetic fac-
tors include DNA methylation and histone modifications 
such as methylation, acetylation or ubiquitylation amongst 
others. Other epigenetic mechanisms are the regulation by 
non-coding RNAs, such as microRNAs, and mechanisms 
that control the higher-level organization of chromatin 
within the nucleus. These epigenetic modifications do not 
occur randomly but are carefully orchestrated [23]. Once in 
place, epigenetic changes can direct gene expression by 
modifying the accessibility of gene promoters and therefore 
facilitating (or avoiding) the recruitment of additional chro-
matin modifying enzymes or transcriptional regulators that 
would drive stem cell differentiation [24-28]. Indeed a recent 
study has demonstrated that the promoter regions of key 
genes in osteogenic differentiation such as BMP2 (encoding 
Bone Morphogenetic protein 2) and ALPL (encoding Alka-
line Phosphatase) are epigenetically locked in MSCs to pre-
vent their expression in non-osteogenic cells [29]. These 
genes have high levels of DNA methylation and low levels 
of histone acetylation. The alteration of this pattern using 
demethylation agents or inhibitors of histone deacetylases 
leads to their transcriptional activation [29]. This idea of an 
epigenetic control of stem cell differentiation has been sup-
ported throughout the years by several studies using chroma-
tin-modifying drugs that can alter the potential of pluripotent 
and multipotent stem cells to differentiate into several linea-
ges.  
 Since most of the current therapies are clearly insuffi-
cient for repairing damaged bone, to control the ability of 
hMSCs to differentiate into bone forming cells is of special 
interest for skeletal tissue engineering. While significant 
progress has been made in unraveling the molecular regula-
tion of hMSCs differentiation, the comprehensive role of 
epigenetic factors in the pathophysiology of skeletal dis-
eases, such as osteoporosis, in humans is however mostly 
unknown at this time.  
 Osteoblast differentiation can be divided into distinct 
stages based on the markers expressed at each stage. The 
first step would consist in the lineage commitment and the 
formation of osteoprogenitors. This step is regulated by mas-
ter transcription factors and the correspondent co-regulators, 
such as RUNX2 (Runt related protein 2) and BMP2. The sec-
ond step would consist in the proliferation of the osteopro-
genitor cells with the expression of growth related genes. 
This step would be followed by the extracellular matrix 
maturation stage, where bone matrix proteins, such as Bone 
Sialoprotein (IBSP), Alkaline phosphatase (ALPL) and Col-
lagen I (COL1A1) would be expressed. After the maturation, 
the extracellular matrix goes through the mineralization step 
that would require the expression of Osteocalcin (OCN) and 
Osteopontin (OPN).  
 Amongst all the factors involved in osteogenesis RUNX2 
seems to be the master regulator since not only is involved in 
the regulation of most osteblastic specific genes, but also 
regulates the expression of its targets in response to different 
signals, incluiding, TGF- , BMP and WNT signalling path-
ways, amongst others. Mutations in Runx2 lead to the arrest 
 
Fig. (1). The multipotency of Mesenchymal Stem Cells. Mesenchymal Stem Cells (MSCs) are capable of self-renewing to produce more 
hMSCs but also, of dividing asymmetrically producing lineage-committed progenitors that will differentiate into the required cell types. 
hMSCs are able differentiate in a variety of cell types of mesodermal germ layer, such as adipocytes chondrocytes and osteoblasts, but they 
can also differentiate into endodermal and ectodermal cells types through a process known as “transdifferentiation”. 
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of osteoblast development and have severe skeletal defects. 
Subunit  of the core binding factor (CBF ) was the first 
known RUNX2 binding partner. However, it has been re-
cently discovered that another transcription factor involved 
in the regulation of OCN, OPN, IBSP and COL1a1 can also 
cooperate with RUNX2 to for osteoblast-specific gene regu-
lation. This factor is known as Osterix (OSX).  
 The canonical Wnt and BMP pathways seem to interact 
together at different steps of osteogenesis. BMP pathway 
operates early during osteogenesis to drive the differentiation 
of MSCs into osteoprogenitors. Later on, the function of Wnt 
signalling is to drive the differentiation of those osteopro-
genitors towards osteoblastic fate. RUNX2 seems to have 
also a key role integrating these pathways. 
2. EPIGENETIC CHANGES AND OSTEOPOROSIS 
 As we previously mentioned, the differentiation of 
hMSCs is achieved through functional interaction between 
transcription factors and epigenetic mechanisms. Changes in 
a specific epigenetic program may directly interfere with the 
differentiation process, ultimately giving rise to abnormal 
gene expression and the development of metabolic bone dis-
eases or even, tumour formation [30]. Amid all bone dis-
eases, osteoporosis is, by far, the most prevalent. This dis-
ease is suffered by millions of people around the world, af-
fecting 1 in 3 women and 1 in 5 men over the age of 50 [31-
33]. Moreover, osteoporotic fractures increase exponentially 
with advancing age and are a major cause of morbidity in the 
elderly, highlighting the clinical importance of this illness 
and its conception as a major problem in public health. 
 Osteoporosis is characterized by a decrease in bone min-
eral density (BMD) and the deterioration of bone microarchi-
tecture. In order to maintain a correct bone homeostasis, the 
processes of bone formation, and bone destruction (known as 
bone “resorption”) are carefully balanced (Fig. 2). Indeed, 
the onset of skeletal pathologies such as osteoporosis or os-
teoarthritis is produced by deregulation of the balance be-
tween bone formation, mediated by bone-forming cells (os-
teoblasts) and bone-resorbing cells (osteoclasts) (Fig. 2). 
Although it seems clear that the development of osteoporosis 
is correlated with an increase in bone resorption, this neces-
sarily has to be associated with an insufficient bone forma-
tion to replace the destroyed bone. Therefore, we need to 
contemplate a possible defect in the activity of the osteocytes 
or bone-forming cells. Indeed, studies in osteoporotic indi-
viduals indicate both a deficient activity of the osteoblasts 
[34] together with an increase in the number of these cells 
becoming apoptotic [35, 36]. Overall, the latest findings 
point at the high relevance of epigenetic changes in complex 
diseases, especially those that, like osteoporosis, develop late 
in life. The increase of the necessary osteogenic activity to 
replace the bone being resorpted requires a correct prolifera-
tion and differentiation of the osteoblastic precursors from 
mesenchymal stem cells. It is possible that this inadequate 
response of the bone-forming cells to the increase in bone 
resorption could be directly related to alterations in the epi-
genetic landscape of genes driving the differentiation of 
hMSCs into osteoblasts.  
 MSCs can differentiate into adipocytes or osteoblasts 
amongst other cells lineages. In the last few years there has 
been increasing evidence pointing to the presence of a fatty 
bone marrow (accumulation of adipocytes) in patients with 
bone diseases such as osteoporosis (Fig. 2). The fact that 
these two processes (adipogenesis and osteogenesis) are mu-
tually exclusive in MSCs was highlighted by the fact that 
inhibition of adipogenesis seems to improve bone develop-
ment and repair [37, 38]. Since both adipose and bone cells 
are differentiated from MSCs, it seems clear that this particu-
lar disease could be a reflection of an imbalance between 
 
Fig. (2). Bone homeostasis and osteoporosis. The maintenance of bone over time requires a balance between bone formation and bone 
breakdown (resorption). This is accomplished by the bone-forming cells and bone-resorpting cells acting in a coordinated fashion. The onset 
of osteoporosis is produced by deregulation of the balance between bone-forming cells (osteoblasts) and bone-resorpting cells (osteoclasts). 
This disease is characterized by an increase of the osteoclastic activity together with a deficient activity of the osteoblast and an increase of 
the number of these cells suffering apoptosis. The low bone-forming activity of the osteoblasts in osteoporosis could be a result of a defect in 
the differentiation of the progenitor MSCs that would preferentially differentiate into adipocytes, producing the effect known as “fatty bone 
marrow” in osteoporotic individuals. 
B
O
N
E 
 
SU
R
FA
C
E 
B
O
N
E 
B
O
N
E 
 
M
A
R
R
O
W
 
	
	
OSTEOBLASTS 
ADIPOCYTES 
OSTEOCYTES 
OSTEOCLASTS 
HUMAN 
MESENCHYMAL 
STEM CELLS SELF 
RENEWAL 
OSTEOBLASTS 
OSTEOGENESIS 
ADIPOCYTES 
ADIPOGENESIS 
LINING CELLS 

OSTEOBLASTS 
ADIPOCYTES 
OSTEOCYTES 
OSTEOCLASTS 
HUMAN 
MESENCHYMAL 
STEM CELLS SELF 
RENEWAL 
OSTEOBLASTS 
OSTEOGENESIS 
ADIPOCYTES 
ADIPOGENESIS 
LINING CELLS 
Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation Current Genomics, 2015, Vol. 16, No. 6    371 
adipogenesis and osteoblastogenesis (Fig. 2). Although the 
molecular mechanisms determining whether a MSCs would 
differentiate into osteoblast or adipocyte lineage are still un-
clear, recent works seem to highlight the importance of epi-
genetic factors in this cell fate decision [39]. Therefore, un-
derstanding the epigenetic mechanisms governing this bal-
ance seems of the upmost importance in order to target and 
treat this disease. Since the activity of epigenetic factors is 
susceptible of being chemically modulated, they constitute 
perfect targets to control gene expression and thus, the iden-
tification of key epigenetic changes together with the pros-
pect of modulate their activity holds great potential for the 
treatment of osteoporosis and other metabolic bone diseases.  
3. EPIGENETIC MECHANISMS REGULATING OS-
TEOGENESIS 
 The differentiation of osteoblasts from MSCs is accom-
panied by profound changes in gene expression. It has been 
shown that two important epigenetic mechanisms, histone 
modification and DNA methylation have a key role regulat-
ing the expression of several genes associated with the os-
teogenic potential of MSCs as well as with the regulation of 
different stages of osteoblast differentiation.  
 High throughput analyses have recently characterized the 
global changes in gene expression and epigenetic landscape 
upon differentiation of human MSC towards the osteogenic 
lineage [40]. Global changes in gene expression during the 
onset of differentiation were associated with a decrease in 
proliferation and up-regulation of genes involved in os-
teoblast function [41, 42]. The differentiation process in-
duces changes in histone methylation and acetylation. It is 
important to note that although global epigenetic changes 
were indeed detected during differentiation, these changes 
were not always linked to changes in gene expression. These 
epigenetic changes not linked to variations in gene expres-
sion were proposed to be part of a pre-patterning mechanism, 
poising genes for activation or repression in preparation for 
later parts of the differentiation program.  
 It has been shown that induction of differentiation is as-
sociated with genome-wide loss of histone acetylation, while 
levels of histone methylation remain practically unchanged 
[40]. Interestingly, analysis of the methylome of MSC from 
different origins (adipose tissue, muscle and bone marrow) 
showed that regardless of their source, MSCs share similar 
genome-wide methylation patterns and that most of the 
promoters involved in lineage-specification were 
hypomethylated in all the different types of MSCs analyzed. 
The hypomethylated regions harbored a combination of 
trimethylated H3K4 and H3K27. This could reflect a wide 
choice of cell fates. On the contrary, early developmental 
genes were DNA hypermethylated and this could be 
accompanied or not with H3K27 methylation, another 
silencing mark [40]. 
 When this genome wide analysis was focused on global 
DNA methylation, they found altered methylation in a very 
low percentage of the CpG sites analyzed (1,273 sites of 
450,000 sites analyzed) [40]. Therefore, DNA methylation 
remains relatively constant during MSCs osteogenic differ-
entiation and does not seem an important factor, quantita-
tively speaking, although these small methylation variations 
could have great impact in the differentiation process. 
Interestingly, the differentiation process of MSCs into a 
specific cell type seems to involve less epigenetic changes, at 
least regarding DNA methylation, than the differentiation of 
pluripotent cells into multipotent committed progenitors 
[43]. 
3.1. Histone Modifications 
 Chromatin refers to the state in which DNA and histones 
are packaged within the eukaryotic nucleus. Chromatin is 
formed by nucleosomes, a basic repeating unit consisting of 
147 bp of DNA wrapped around an octamer of two mole-
cules each of histones H2A, H2B, H3 and H4.  
 The degree of chromatin packaging greatly determines 
whether a given DNA sequence is or not available to be tar-
geted by a specific transcription factor. The loosely packaged 
chromatin, known as “euchromatin”, facilitates the accessi-
bility of transcription factors to the DNA and therefore, gene 
transcription. On the other hand, tightly packaged chromatin, 
also called “heterochromatin”, would block gene expression 
by physically impeding the access of transcriptional regula-
tors to the DNA.  
 The chromatin conformation would be altered in re-
sponse to covalent post-translational modification of the 
flexible N-terminal histone tails that protrude from the nu-
cleosomes. The complexity of these modifications depends 
not only on the amino acidic residue modified, but also on 
the type of chemical group added. These modifications in-
clude acetylation, methylation, phosphorylation, ubiquityla-
tion and SUMOylation amongst others [21, 44]. In general 
terms, histone modifications can be classified into those that 
correlate with transcriptional activation (such as acetylation 
and phosphorylation) and those related to transcriptional 
repression (such as methylation, ubiquitilation and SUMOy-
lation). Euchromatin, the more open and relaxed form of the 
chromatin is, in general, rich in acetylated lysine residues, 
such as acetylated histone 3 lysine 4 (H3K4Ac) or acetylated 
lysine 9, (H3K9Ac), while the more compacted form of 
chromatin, heterochromatin, presents low levels of acetyla-
tion and high levels of histone methylation, such as trimethy-
lated H3K9 (H3K9m3) or trymethylated H3K27Me 
(H3K27m3) [45-47] although methylation of H3K4 is nor-
mally related to gene activation. Different modifications 
would work in a coordinated way to induce structural 
changes in the chromatin and therefore modify the accessi-
bility of transcription factors to regulatory sequences, allow-
ing the regulation of gene expression in a time and tissue-
specific manner. This is known as the “Histone Code Hy-
pothesis” [21]. 
3.1.1. Histone Acetylation and Deacetylation 
 One of the most studied epigenetic factors is histone ace-
tylation. The transfer of an acetyl group from an acetyl-CoA 
molecule to specific lysine residues located at the histone 
tails is catalysed by histone acetyltransferases (HATs), 
whereas the opposing effect, the elimination of an acetyl 
group from a lysine residue is catalysed for the histone 
deacetylases (HDACs) (Fig. 3A). When this transfer occurs, 
the acetyl group neutralizes the positive electric charge of the 
lysine residue and thus relaxes the interaction of the histone 
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tail with the DNA, which is negatively charged, a process 
defined as “nucleosome opening”. The chromatin structure, 
once relaxed, makes the DNA accessible for different tran-
scription factors or the transcription machinery. In addition, 
this acetylated residue could also act as a docking site for 
regulatory factors that recognise acetylated lysine residues 
trough a specific domain called bromodomain. The level of 
acetylation at the histone tails, thus depends on the balance 
between the activities of HDACs and HATs [21].  
 The analysis of the global epigenetic changes occurring 
during osteogenic differentiation of hMSCs, revealed that 
induction of differentiation produces a genome-wide reduc-
tion of the levels of acetylated H3K9 and H3K27 [40], al-
though these reduction was considerably less important 
when the analysis was restricted only to regions surrounding 
gene promoters (Fig. 3A). Reduction in acetylation occurred 
at genes involved in gene regulation, cellular survival, 
growth and proliferation. Other authors have also found a 
reduction in histone acetylation accompanying the differen-
tiation of hMSCs into myocytes, adipocytes, astrocytes or 
oligodendrocytes [48-50]. These results suggest that histone 
deacetylation might be a common step in cellular differentia-
tion and could be related to condensation of chromatin at 
specific regions to restrict transcription and differentiation 
potential into other cell lineages. This study also corrobo-
rated that the few genes whose transcription was activated 
during differentiation were enriched in acetylated histone 
marks [40]. 
 HDACs are classified into four different classes. Class I 
includes HDACs from 1 to 4. Class II includes HDACs from 
5 to 10. Class III includes Sirtuins (Silent Mating Type In-
formation Regulation 2 Homolog) 1 to 7, a special type of 
HDACs dependent on Nicotinamide adenine dinucleotide 
(NAD), and finally, only one member, HDAC11, would de-
fine Class IV.  
 Several studies regarding the role of histone acetylation 
in the control of osteogenesis used inhibitors of HDACs 
whose effect leads to an important increase in the histone 
acetylation levels (hyperacetylation). 
 While in vitro inhibition of HDACs in MSCs derived 
from umbilical cord or adipose tissue with valproic acid or 
sodium butyrate, leads to a decrease in chondrogenic or adi-
pogenic differentiation, these treatments seem to have a posi-
tive effect on osteogenic differentiation [51]. Similarly, 
trichostatin, another HDAC inhibitor, was shown to increase 
osteoblast maturation and calcium deposition in cultures of 
bone marrow derived MSCs [52]. Interestingly, Cho et al. 
(2005) showed that treatment with valproic acid, leading to 
histone hyperacetylation, induced osteogenic differentiation 
and subsequent up-regulation of osteogeneic genes (OSX, 
OPN, RUNX2 and BMP-2) in adipose and bone marrow de-
rived MSCs. However, treatment of the same cells with a 
structural analogue of valproic acid lacking HDAC inhibitor 
activity did not show this osteogenic induction, clearly indi-
cating that the effect of valproic acid as an inductor of os-
teogenesis was directly related to its HDAC catalytic activ-
ity. This HDAC inhibitor has also been shown to trigger the 
proliferation of MSCs [53-55]. Similarly to what has been 
described in human MSCs, in vitro treatment of rat adipose-
derived MSCs with trichostatin promotes osteogenic differ-
entiation, an effect that seemed to be mediated by an increase 
of histone acetylation at the RUNX2 promoter (suggesting 
RUNX2 up-regulation), and was also dependent on BMP 
signalling [56]. Overall it seems clear that treatment with 
HDAC inhibitors, and therefore histone hyperacetylation, 
promotes osteogenic differentiation in MSCs and that in-
crease in histone acetylation at RUNX2 and its subsequent 
activation plays a key role in this response.  
 Although the effect of HDAC inhibitors over MSCs os-
teogenic differentiation in vitro seems to be consistent, the 
results using these inhibitors in vivo are controversial and 
seem, to an extent, determined by the mouse strain used [57, 
58] or by the state of the immune system of the subject. Val-
proate overall was shown to reduce BMD in young rats [57] 
and mice [58]. While in some cases the treatments led to an 
increase in osteocalcin in serum, this was not related to any 
change in osteoblast activity [58]. Mice treated with SAHA 
(suberanilohydroxamic acid), another HDAC inhibitor, also 
displayed a decrease in the volume of trabecular bone [59]. 
Opposing these results, in other studies, mice treated with 
SAHA showed increased local osteoblast activity and in-
creased mineral apposition and bone formation rate follow-
ing treatment [51, 55, 60] suggesting that this HDAC inhibi-
tor can cause bone loss even while increasing the activity of 
mature osteoblasts [59]. 
 In mice, knock down of HDAC4 in chondrocytes leads to 
an increase in bone formation, an effect correlated with an 
increase in RUNX2 activity [61]. However, more recently, 
other results have appeared pointing to a negative effect of 
some HDACs depletion on bone formation. Conditional 
knock out of HDAC3 in mice was shown to interfere with 
bone formation and promote adipogenesis [62]. These results 
are clearly opposed to those obtained in several in vitro stud-
ies [55, 63-65]. Thus, there is a clear discrepancy between 
the effects of HDAC3 abrogation in vitro in osteoblast cell 
lines (activation of osteoblastogenesis) and the in vivo dele-
tion of HDAC3 in osteoprogenitor cells expressing OSX (de-
creased osteogenic activity and bone loss). A possible expla-
nation for these contradictory results is that contrary to the 
permanent effect of a genetic deletion, HDACs inhibitors 
have short half-lives in serum and might induce only tempo-
ral changes in chromatin structure and gene expression. Be-
sides, whereas non-proliferating cells would be resistant to 
the toxic effects of HDAC inhibitors they would still be sus-
ceptible to HDAC3 deletion [66]. While the different out-
comes of HDAC deletion could be explained based on the 
previous explanations and in the fact that those studies used 
different cell types, further work needs to be done in order to 
clarify this issue. 
 The role of HDACs inhibitors on bone formation in hu-
mans is also somehow arguable. Patients suffering for some 
neurological conditions (epilepsy, mood disorder and bipolar 
disease) treated with valproic acid showed an important de-
crease in bone mass [59], whereas in other studies, markers 
of bone resorption after valproate treatment were reported to 
decrease, increase or even be unaffected [67-69]. The dis-
agreement between these studies was attributed to the fact 
that general HDAC inhibitors, such as valproate, could target 
a wide range of HDACs with different specificities or could 
have an effect in enzymes others than HDACs. Besides, 
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since this analysis was done in patients suffering from di-
verse neurological conditions, the authors considered that the 
results could have also been impacted by the different co-
horts of patients analysed [59].  
 Sirtuin 1, a member of HDAC Class III family, encoded 
by the SIRT1 gene, has been recently shown to be a key 
regulator of bone mass due to its role as an inhibitor of scle-
rostin expression. Sclerostin, encoded by the SOST gene, 
interferes with the Wnt signalling pathway by binding to 
LPR5/6 receptors and therefore has a negative effect on bone 
formation. Sirtuin1 protein represses the expression of the 
SOST gene by means of H3K9 deacetylation at the SOST 
promoter (Fig. 3B). Cohen-Kfir et al. (2011) showed that 
mice in which a copy of the SIRT1 gene had been deleted 
displayed a reduced osteoblast activity leading to a reduced 
bone mass [70], an effect probably mediated by an increase 
in the levels of sclerostin.  
 Several works analysing the epigenetic regulation of os-
teogenic genes have focused on the regulation of OCN ex-
pression. The OCN promoter has, when active, high levels of 
the acetylated histones H3 and H4 [71, 72]. The activation of 
this gene depends on an active acetylation of these residues 
as well as on a decrease in DNA methylation [71, 73, 74]. It 
has also been shown that vitamin-D dependent activation of 
OCN is mediated by nucleosome remodelling favouring 
transcriptional activation [75]. Following these structural 
changes at the OCN promoter, a protein complex containing 
RUNX2 as well as other chromatin remodelling factors 
would bind the OCN promoter to induce its activation [76, 
77] (Fig. 3C). Although the transcriptional co-activator p300 
has been shown to interact with RUNX2 at the OCN pro-
moter, its HAT catalytic activity was not found to be respon-
sible for the increase in histone acetylation preceding OCN 
transcriptional activation, as the increase of OCN expression 
in the presence of p300 was not abolished when a catalyti-
cally death version of this HAT is used [72]. However an-
other HAT, PCAF (p300/cyclic AMP receptor element-
binding protein associated factor) is able to interact with 
p300 to promote OCN expression and was suggested to be 
responsible of the HAT mediated activation of OCN expres-
sion [72]. Indeed it has been recently demonstrated, that 
PCAF can interact and acetylate RUNX2 leading to an in-
crease of osteogenic markers expression and mineralization 
[78]. It has been suggested that the enhanced RUNX2 activ-
ity after its acetylation by PCAF could be due to an increase 
in its DNA binding capacity. 
 Many HATs are actually lysine acetyl transferases as 
they are able to acetylate other non-histone proteins modulat-
ing their activity. Jeon et al. (2006) showed that BMP2-
mediated induction of osteogenesis requires the acetylation 
of RUNX2 by p300 and that RUNX2 activity is inhibited by 
HDAC4/5. This acetylation increases RUNX2 activity and 
inhibits degradation of RUNX2 by SMURF1 (Fig. 3C). 
When RUNX2 is deacetylated by the action of HDAC4 and 
HDAC5, this allows the ubiquilitation of Runx2 by Smurf 
and its subsequent degradation [79]. Therefore, the activity 
of RUNX2 is tightly controlled by the equilibrium between 
the activities of HAT and HDACs. 
 It is important to highlight that there are other HATs, 
including MOZ and MORF [80], that have been shown to 
interact with RUNX2 and could have a role in osteogenic 
differentiation either by modulating the activity of the oste-
genic master regulator RUNX2 or by directly acetylating 
histones at their target promoters.  
3.1.2. Histone Methylation 
 Histone methylation can occur in lysine or arginine resi-
dues located at the histone tails [21]. Depending on the resi-
due methylated, this epigenetic signal could be related to 
gene activation (methylation of H3K4), or to gene repression 
(methylation of H3K27 or H3K9). If these two types of 
modifications take place at the same promoter region (some-
thing known as a “bivalent mark”) the gene in question 
would be in a poised state, a phenomena reported in pluripo-
tent stem cells [81]. 
 The level of methylation at the histone tails is governed 
by the opposing activities of histone methyltransferases 
(HMTs) and histone demethylases (HDMTs). 
 There are two main families of HMTs with opposite ac-
tivities. The Polycomb (PcG) family, carries out the methyla-
tion at lysine 27 of histone H3 (H3K27), a mark, as we pre-
viously mentioned, linked to gene silencing. The other 
group, known as the Trithorax (TrxG) family, methylates 
H3K4, a mark related to gene activation (Fig. 4B and 4C). 
Enhancer of Zeste 2 (EZH2) is a member of the PcG family 
and a component of the Polycomb repressor complex 2 
(PRC2). This protein catalyzes the di-and tri- methylation of 
the lysine 27 at Histone H3 (H3K27me2 and H3K27m3) a 
modification that would be later recognized by the Polycomb 
repressor complex 1 (PRC1) leading to the transcriptional 
repression of the targeted genes. Wei et al. (2011) [82] found 
that the HMT EZH2 has a key role in the inhibition of MSC 
differentiation. EZH2 targets the promoter of RUNX2 and 
promotes its inactivation, by means H3K27 methylation. 
EZH2 can be inactivated through of CDK1 dependent phos-
phorylation that disrupts its binding with the rest of compo-
nents of the PcG complex. CDK1 is one of the major kinases 
controlling the transition from the G2 to the M phase of the 
cell cycle and has a key role in regulating proliferation and 
lineage specification in stem cells [83]. EZH2 inactivation 
by CDK1 leads to the reduction of the H3K27me3 at the 
RUNX2 promoter, its subsequent activation, and therefore, 
the triggering of osteogenic differentiation. Therefore, CDK1 
and EZH2 have a key role in osteogenic differentiation of 
MSCs. 
 Global analyses of the epigenetic changes undergone 
during osteogenic differentiation of hMSCs have shown that 
total levels of H3K4m3 and H2K27m3 remained mostly un-
changed during differentiation (Fig. 4A). However, when the 
analysis was restricted to regions surrounding gene promot-
ers they found that, although no changes were detected again 
for the H3K4m3 mark, the silencing mark H3K27m3 was 
overall enriched at these promoter regions, coinciding with 
the decrease in histone acetylation mentioned in the previous 
section. Changes in H3K27m3 affected only a few differen-
tially expressed genes. However, this mark was found to be 
enriched mainly in promoters of genes involved in neuro-
genesis suggesting that the neurogenic potential of hMSCs is
374    Current Genomics, 2015, Vol. 16, No. 6 Pérez-Campo and Riancho 
 
Fig. (3). Role of histone acetylation in hMSCs differentiation into osteoblasts. (A) Differentiation of hMSCs into osteoblasts produces a 
genome-wide reduction of the levels of acetylated H3K9 and H3K27, together with an increase in the histone acetylation at the promoters of 
osteogenic genes. (B) Sclerostin, the product of the SOST gene, binds to the LPR5/6 receptors inhibiting the activation of the wnt pathway 
and therefore, osteogenic differentiation. HDAC SIRT1 would activate osteogenesis by deacetylating SOST promoter and thus, inhibiting its 
expression. (C) Activation of OCN is mediated by an active (acetylated) RUNX2 protein and by the acetylation of histones at its promoter, 
mediated by the HAT p300. 
restricted once osteogenic differentiation has been initiated. 
Actually, the majority of craniofacial bones are generated 
during embryogenesis from cranial neural crest cells but this 
potential is suppressed in more posterior neural crest cells by 
the action of hometotic (HOX) genes. A recent work high-
lighting the role of EZH2 in osteogenesis has shown that 
craniofacial bone is fully prevented in Ezh2 conditional 
knockout mice due to in an important up-regulation of HOX 
genes transcription in neural crest cells, (Fig. 4B) showing 
that the development of craniofacial bones in mammals also 
depends on epigenetic mechanisms [84]. 
 Members of the TrxG groups, such as the Histone methyl-
trasnferases MLL1 and MLL2, antagonize the action of PcG 
proteins, such as EZH2, and therefore work as activators of 
genes expression. They catalyzed the di and tri- methylation of 
H3K4, an activation mark. In humans, the TrxG complexes 
contain one of the MLL proteins and a core module consisting 
of four proteins (WDR5, RBbp5, Ash2 and DPY-30)  
(Fig. 4C). All members of the complexes are essential and 
loss or malfunction of any of the subunits of the complex 
results in a decrease on H3K4 di- and tri-methylation.  
Nayak et al., [85] have recently shown that inactivation of
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Fig. (4). Role of histone methylation in hMSCs differentiation into osteoblasts. (A) Total levels of H3K4m3 and H2K27m3 remain 
mostly unchanged during differentiation however the silencing mark H3K27m3 was overall enriched at regions surrounding the promoter 
regions. (B) Polycomb repressor complexes 1 and 2 (PCR1 and PCR2) catalyse the H3K27 methylation leading to gene silencing. (C) BCOR 
interacts with the KDM2b) demethylase, and inhibits its recruitment to their target promoters and hence the demethylation of lysine residues 
driven by this enzyme, mainly H3K36 and H3K4. (D) MLL genes, belonging to the Trithorax family, methylate H3K4 leading to gene activa-
tion. (E) BMP-induced bone formation is mediated by the binding of Zfp521 to the promoter of Zfp423 and subsequent increase in H3K9 
acetylation and decrease of histone H3K9 methylation. 
the SUMO-specific isopeptidase SENP3 leads to an impor-
tant downregulation of genes belonging to a specific subfam-
ily of HOX genes, the DLX genes. One of the members of 
this family, DLX3 (Distal-less Homeobox 3) was shown in 
the same work to regulate the differentiation of dental folli-
cle stem cells (DFSCs) into mature osteoblast by controlling 
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RUNX2 expression (Fig. 4C). This group showed that 
SENP3 catalyzes the de-SUMOylation of RbBP5 one of the 
core proteins of the TrxG complexes. This step is crucial to 
have a functional TrxG complex, and therefore, deletion of 
SNP3 leads to a decrease in the methylated H3K4 levels at 
the DLX3 promoter and a decrease in the presence of RNA 
Polymerase II at that promoter. The deficient activation of 
DLX3 thus translates into a deficient activation of Runx2 
and ultimately to a defective osteogenic differentiation [85] 
(Fig. 4C). 
 The opposite reaction to histone methylation, that is the 
removal of methyl groups from specific lysine residues at the 
histone tails, is carried out by histone demethylases 
(HDMTs). 
 Several works have recently pointed to a key role of 
these enzymes in the decision of cell fate [46, 86-88]. An 
article from Fan et al. [89] studying the BCOR (BCL6-Co-
Repressor) gene was one of the first works to link changes in 
the histone methylation levels with the ability of hMSCs to 
initiate osteogenic differentiation. The BCOR gene [90] is 
frequently mutated in patients with the Oculofacialcardi-
odental syndrome (OFCD) characterized by craniofacial ab-
normalities and extremely long teeth roots. The BCOR pro-
tein is able to interact with histone deacetylases and demeth-
ylases suggesting that this protein might exert its function by 
means of chromatin modification [91, 92]. Indeed, BCOR 
interacts with the JHDM1b (KDM2b) demethylase, and 
seems to inhibit the recruitment of JHDM1b to their target 
promoters and hence the demethylation of lysine residues 
driven by this enzyme, mainly H3K36 and H3K4. In OFCD 
patients, the mutated version of the BCOR gene fails to re-
cruit JHDM1B to the promoter of the AP-2a (Activating 
Enhancer-Binding Protein 2-Alpha), a transcription factor 
essential for craniofacial development [93, 94], that mediates 
the elevated osteogenic capacity of MSCs from OFCD pa-
tients, this leads to an increase in H3K4m3 and the subse-
quent activation of AP-2a transcription, therefore explaining 
the appearance of some of the characteristic phenotypes of 
OFCD patients, such as enlarged roots of canine teeth (Fig. 
4D). 
 Another important work from the same group, aimed to 
further explore the role of these enzymes in cell fate deter-
mination, analysed the expression of histone demethylases in 
MSCs in response to osteogenic induction mediated by 
BMP4/7. This group found that histone demethylases 
KDM4B [95] and KDM6B [87] were importantly up-
regulated following osteogenic induction and that knock-
down of any of these two histone demethylases either in vivo 
or in vitro blocked on one hand osteogenic differentiation 
but clearly drives adipogenic differentiation on the other 
hand [86]. Particularly, knockdown of KDM6B seemed to 
inhibit expression of key osteogenic proteins, such as IBSP, 
SPP1 and OCN. To determine whether this activity of 
KDM6B was directly dependent on its HDM activity, the 
authors developed a catalytically dead version of the protein. 
The mutated form of the protein, unlike its wild type version, 
was unable to rescue osteogenic differentiation of hMSCs in 
a mouse where KDM6B activity has been silenced, indicat-
ing the key role of this catatytic activity in the regulation of 
osteogenic gene expression. In agreement with this work, Xu 
et al. [96] recently found that KDM6b has a similar role in 
dental mesenchymal stem cells. KDM6B was recruited to the 
promoter of the bone morphogenetic protein 2 (BMP2), lead-
ing to the removal of H3K27m3 marks and therefore induc-
ing its activation [86]. 
 Bone morphogenetic proteins (BMPs) are known to drive 
cell fate towards osteogenesis. Although initial reports led to 
the idea that BMPs inhibited adipogenic differentiation [97] 
there is some works reporting some positive effects of BMPs 
on the adipogenic differentiation under certain conditions 
[98-101]. The further progression into osteogenesis induced 
by BMP induction is mediated by SMAD activation, that 
would, in turn drive the activation of osteogenic transcription 
factors, such as RUNX2 and Osterix (OSX). On the other 
hand, the induction of adipogenesis mediated by BMP2 is 
mediated by the Smad-associated cofactor Schnurri3 [100] 
and the pre-adipocyte commitment factor zinc finger protein 
423 (Zfp423) [102] that would, in turn, activate the perox-
isome proliferator-activated receptor (PPAR), the master 
regulator of adipogenic genes. 
 A recent work by Addison et al. [39] shows that deletion 
of another zinc finger protein (Zfp521) that regulates lineage 
progression, impairs BMP-induced bone formation and in-
duces the differentiation of MSCs towards adipose tissue 
formation. This is mediated by the binding of Zfp521 to the 
promoter of Zfp423 and subsequent increase in H3K9 acety-
lation and decrease of histone H3K9 methylation. Although 
further work would be needed in order to elucidate the par-
ticular epigenetic mechanisms driven by the binding of 
Zpf521 to the Zpf423 promoter these findings support previ-
ous evidence that MSCs lineage commitment is epigeneti-
cally regulated by histone modifications [86, 103].  
3.2. DNA Methylation 
 The methylation of the cytosine in 5 -position at a CpG 
dinucleotide is a well-characterized epigenetic modification 
[104]. While this epigenetic mark was initially considered to 
mediate stable gene silencing, recent studies have shown that 
the effect of DNA methylation on gene expression highly 
depends on the CpG density and that, promoters with low 
methylated CpG content can be active or inactive [105].  
 Although there is some controversy [106, 107], DNA 
methylation is considered by many to be the initiating event 
leading to the subsequent changes in the epigenome. In this 
context, it has been suggested that methylated DNA would 
recruit methyl-CpG binding proteins that would, in turn, re-
cruit histone deacetylases (HDAC) leading to histone deace-
tylation and therefore gene silencing [73, 108]. On the other 
hand, more recent discoveries indicate that gene silencing 
could be initiated by histone deacetylation followed by sub-
sequent histone and DNA methylation of the CpG islands 
[109]. It has also been proposed that both mechanisms could 
coexist and work depending on the cell context or genomic 
locus.  
 DNA methylation patterns are very dynamic during the 
development of the organism. After the methylation patterns 
of the gametes are erased during blastocyst formation, DNA 
methylation is extensively reprogrammed, up to the post-
implantation epiblast, through the activity of the “de novo” 
Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation Current Genomics, 2015, Vol. 16, No. 6    377 
DNA methylatransferases DNMT3a and DNMT3b [22, 110]. 
Mutations in DNMT3 are associated with a rare syndrome 
called “Immunodeficiency Centromeric Instability and Fa-
cial Anomalies type I” (ICF1). A recent work using cells 
from an individual suffering from this syndrome, has shown 
that Induced Pluripotent Stem Cells (iPs) derived from fibro-
blasts of this patient, exhibited global loss of non CG methy-
lation and selective hypomethylation at centromeric regions, 
specific gene promoters and enhancers. These hypomethy-
lated regions were preserved even when the iPs were differ-
entiated into MSCs [111] and were similar to those found in 
ICF1 somatic cells, indicating the existence of a specific 
methylome defects in ICF1 cells. These results also under-
score the importance of DNMT3-mediated DNA methylation 
in the establishment of a correct methylation pattern. A dif-
ferent DNA methyltransferase, DNMT1 would be in charge 
of maintaining and propagating the methylation patterns 
through mitosis by reproducing methylation patterns from a 
hemi-methylated substrate after DNA replication [22]. Inac-
tivation of this enzyme in mice results in loss of genomic 
imprinting and leads to early embryonic lethality, showing 
the importance of this protein for development [112, 113]. 
Although reduced DNMT1 activity might be expected to 
lead to global demethylation, loss of DNMT1 in vitro only 
induces demethylation of a subset of key genes [114, 115]. 
In support of this idea, a recent work has demonstrated that 
OCT4 and NANOG bind to the DNMT1 promoter to coop-
eratively induce its expression and to maintain the methyla-
tion of genes associated with senescence and developmental 
regulators [116] (Fig. 5). 
 High-throughput analysis of the methylome of MSCs 
derived from different adult tissues has revealed that there is 
a core of 1755 hypermethylated genes shared by all the 
hMSCs independently of the source tissue, supporting a 
common origen of all these cells. This set of hypermethy-
lated genes was enriched in early developmentally regulated 
genes and probably reflects the functional blocking of older 
developmental programs that are not longer enabled [117]. 
Interestingly, it has also been recently shown, that, inde-
pendently of the developmental lineage they specify, most of 
the promoters of genes whose expression is related to spe-
cific cell types are hypomethylated [43], even though the 
nature of the MSCs analysed preclude their differentiation 
into some of those lineages. This clearly suggests the exis-
tence of a transcriptionally permissive state in hMSCs that is 
not necessarily related to their differentiation potential [118, 
119]. 
 Many of the evidences regarding the involvement of 
DNA methylation in the differentiation resulted from study-
ing the effects of demethylating agents. One of them, 5-aza-
citydine (AzadC), is incorporated in DNA during cell prolif-
eration instead of endogenous cytosine, inhibiting DNMT1 
activity and therefore, reducing DNA methylation [120, 
 
Fig. (5). Role of DNA methylation in hMSCs differentiation into osteoblasts. HMSCS differentiation requires both the activation of 
genes involved in the developing of a specific cell type and the suppression of genes responsible for cell stemness. OCT4 and NANOG bind 
to the DNMT1 promoter to cooperatively induce its expression and to maintain the methylation of genes associated with senescence and 
developmental regulators. 
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121]. Indeed, it has been demonstrated that treatment of 
hMSC derived from adipose tissue of aged individuals with 
AzadC induces proliferation and increases osteogenic poten-
tial of those cells [122]. In the same direction, Zhu et al. 
(2014) recently published a work showing that the os-
teogenic capacity of hMSCs obtained from umbilical cord 
was enhanced in absence of the methyltransferase DNMT3b 
when the cells are exposed to factors inducing osteogenesis 
[123]. 
 As previously stated, stemness genes such as OCT4 and 
NANOG are hypomethylated in undifferentiated stem cells 
but became highly methylated during differentiation [124, 
125]. Besides NANOG and OCT4, Berdasco et al. (2012) 
have described the regulation by DNA methylation of PI-
WIL2, (Piwi-like RNA-Mediated Gene Silencing 2), another 
gene involved in stem cell maintenance [126]. In addition to 
the methylation of stemness genes, the differentiation poten-
tial of MSCs seems to be restricted through the methylation 
of other lineage-specific promoters [118]. Importantly, Bo-
quest et al. (2007) [118] found that the methylation state of 
adipogenic genes in adipose MSCs was more permissive 
than that of endothelial genes, such as CD31 or CD144. The 
methylated state of CD31 and CD144 in undifferentiated 
adipose-derived hMSCs suggest an important limitation in 
their endothelial potential. Indeed, when these cells are 
grown under conditions that promote endothelial differentia-
tion, there is only a minimal decrease in DNA methylation 
and a marginal up-regulation of CD31 and CD144. Thus, 
CpG methylation profiles in undifferentiated hMSCs may 
dictate lineage-specificity of differentiation. This restriction 
in their differentiation potential would obviously limit their 
therapeutic applications. In order to establish if these differ-
ential potentials of hMSCs are the result of differences in 
their epigenetic profiles, Aranda et al. (2009) established a 
relation between the different levels of cell differentiation 
and their epigenetic signatures using genome-wide ap-
proaches [127]. This group analysed the histone modifica-
tions and DNA methylation marks at pluripotency and dif-
ferentiation genes in ES cells, multipotent adult progenitor 
cells (MAPCs) and MSCs and Multipotent Adult Stem Cells 
(ADSC). Their analysis showed that the cells with greater 
differentiation potential (ES cells) showed a profile with 
higher epigenetic repression of differentiation genes both at 
the level of DNA methylation and histone modifications. 
This contrasted with the epigenetic profile of MSCs and 
ADSC, where genes controlling differentiation showed ac-
tive epigenetic profiles. Interestingly, MAPC had an inter-
mediate profile with only the presence of repressive histone 
modifications, but not associated with DNA methylation at 
the differentiation genes. This interesting work clearly shows 
that the loss of potential is correlated step by step to the ac-
quisition of epigenetic marks at the differentiation loci. 
 The significance of promoter methylation in osteoblast-
specific gene regulation is underscored by recent studies 
showing that the expression of RUNX2, DLX5, OSX, OCN, 
RANK, ALPL, SOST and OPG [74, 128-133] correlates with 
their promoter methylation status. In agreement with these 
previous works, Zhou et al. (2009) described that treatment 
of MSCs with AzadC prior to their culture in osteogenic me-
dia significantly promoted osteogenic differentiation, as de-
termined by increased Alkaline Phosphatase (ALPL) activty, 
and increased mineralization. This was also accompanied by 
enhanced expression of osteogenic genes (DLX5, RUNX2, 
COL1a1, OSX, and OCN) and correlated with a decrease in 
methylation of genomic DNA [134].  
 DNA methylation is catalized by DNA-methyltrans- 
ferases and depends on the presence of a methyl donor, nor-
mally S-adenosylmethionine (SAM). SAM is a key molecule 
for mammalian cells since a reduced level of SAM leads to a 
reduced activity of methyltransferases and the subsequent 
demethylation of a variety of molecules. Different methyl-
transferases regulate the incorporation of methyl groups in 
molecules other than DNA, including proteins [135, 136], 
lipids [137], mRNA [138], and other small molecules [139]. 
As described in the previous section, methylation of lysine or 
arginine residues located at the histone tails can induce or 
repress gene expression, but also the activity of non-histone 
proteins can be regulated by methylation. In accordance to 
previous works, Vaes et al. (2010) [140] described that peri-
odate oxidized adenosine (ADOX), an inhibitor of SAM-
dependent methyltransferases, increases osteogenic gene 
expression under normal culture conditions, similar to the 
effect described for Aza-dC. However, they showed that 
under differentiation conditions ADOX inhibits appropriate 
osteoblast gene expression. In contrast with the effects of 
AzadC and ADOX on mRNA expression under non-
osteogenic conditions, under induction of osteogenic differ-
entiation, ADOX-repressed BMP2-induced mRNA levels of 
Alp, Osx and Ocn, all genes downstream of Runx2. How-
ever, expression of the early inducers of osteogenesis Dlx5 
and Msx2 (upstream of Runx2) and mRNA and protein ex-
pression of Runx2 itself remained unchanged by ADOX. 
These results suggest that RUNX2 activity depends on 
methyltransferase activity. Therefore, global SAM-
dependent demethylation leads to impaired osteoblast differ-
entiation despite the fact that DNA hypomethylation can 
increase mRNA levels. 
 Overall it seems clear that the differentiation of MSCs 
into osteoblast requires an active DNA demethylation. Zhang 
et al. (2011) [130] revealed that the demethylation of CpG 
regions at the promoters of osteogenic genes and the subse-
quent increase in their expression levels was associated to a 
transcriptional up-regulation of the Growth Arrest And 
DNA-Damage-Inducible, Alpha (GADD45A) protein. In-
deed, knockdown of Gadd45a by means of an shRNA inhib-
its the DNA demethylation of osteogenic gene promoters, 
leading to an up-regulation of their expression under differ-
entiating culture conditions. Recent data suggests that Nu-
cleotide Excision Repair (NER) is involved in the demethy-
lation of osteogenic gene promoters. According to the 
mechanism described by Schmith et al. (2009) [141] for the 
TAF12 promoter, GADD45A can be recruited to a specific 
promoter DNA and then trigger its demethylation by recruit-
ing the NER complex. The hypomethylated state of the pro-
moter would then allow for the binding of RNA polymerase 
I, and the transcription of RNA. 
4. ENVIRONMENTALLY-INDUCED EPIGENETIC 
CHANGES 
 It is well known that skeletal growth can be modified by 
environmental factors, such as nutrition and physical activ-
ity. Recent studies provided mounting evidence that the ef-
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fect of these environmental factors on bone metabolism is 
mediated by epigenetic factors. 
 While nutri-epigenetic studies have been focused on the 
effect of nutrition during pregnancy and breastfeeding, there 
is also evidences pointing to an effect of some nutrients on 
epigenetic programs during adulthood [142]. Of all nutrients 
influencing bone metabolism, calcium is probably the most 
studied. The effect of calcium on BMD could be reflecting 
changes in the epigenetic pattern of genes regulating bone 
metabolism. Indeed a recent study shows that calcium can 
act regulating the activity of DNMT3b and DNMT1, and to a 
lesser extent of DNMT3a [143].  
 Although nutritional factors have an influence on bone 
metabolism, probably the most important factor affecting 
skeletal growth is fluid shear stress tension. Fluid shear 
stress [144] and compression [145-147] can influence os-
teogenic differentiation. Pressure and fluid flow-induced 
shear stress may be the dominant mechanical stimuli for 
mesenchymal stem cells (MSCs) within the bone marrow 
[148], while tension and compression are suspected to be 
more important in the periosteum. There is evidence that 
bone marrow-derived MSCs increase the expression of Os-
teopontin (OPN) and OCN twenty-four hours after fluid flow 
compared to static controls [149]. In the last few years there 
has been increasing interest in the study of how mechanical 
signals could alter the epigenetic status of key osteogenic 
genes and therefore have a key role in mechanotransduction, 
that is, the process by which cells convert physical stimuli 
into biochemical responses. Arnsdorf et al. (2010) [150] 
showed for the first time that the mechanical microenviron-
ment is able to induce epigenetic changes. In this study they 
designed a novel protocol to promote MSCs differentiation 
by the application of a mechanical stimulus. They described 
and increase in OPN expression levels in MSCs subjected to 
dynamic fluid flow stimulus, and this increase in expression 
levels was related to a decrease in the DNA methylation at a 
specific region in the OPN promoter. Importantly, Mechani-
cal stimulation can also induce epigenetic changes in human 
MSCs through a different epigenetic mechanisms, that is, by 
altering the histone acetylation levels [151]. MSCs subjected 
to mechanical strain had a reduced histone deacetylase 
(HDAC) activity and therefore showed overall higher levels 
of histone acetylation. 
5. FUTURE PERSPECTIVES 
 It seems clear that owed to their ease of isolation and 
characteristics, the future treatment of bone diseases relies on 
the use of hMSCs. To be able to use these cells successfully, 
it is necessary to be able to define and tightly control the 
conditions that promote their differentiation, including the 
epigenetic changes involved. The investigations overtaken 
during the last decade have been crucial to make a progress 
in this direction. Understanding the epigenetic mechanisms 
governing MSCs differentiation is crucial to maintain 
stemness. In addition, understanding these epigenetic 
changes would ultimately allow us to use chemical agents to 
promote or avoid specific epigenetic modifications thus, con-
trolling the differentiation process. 
 It seems now widely accepted that the use of in vitro dif-
ferentiated MSCs has more advantages for their therapeutic 
use than the use of MSCs in their undifferentiated form. 
However, there are increasing evidences indicating that 
MSCs might experiment some loss of potential or premature 
senescence during in vitro culture, which would seriously 
hamper their use for therapeutic porpoises. The changes tak-
ing place in culture might be a reflection of epigenetic de-
regulation and therefore are also susceptible to be controlled. 
Although some techniques like the use of 3D spheroid cul-
ture instead of monolayer culture seems to somehow amelio-
rate this loss of potential during in vitro culture, future ef-
forts should be aimed to unravel the cause of these changes 
and develop techniques in order to preserve MSCs properties 
during in vitro culture. 
CONFLICT OF INTEREST 
 The author(s) confirm that this article content has no con-
flict of interest. 
ACKNOWLEDGEMENTS 
 Suppoted by a grant from Instituto de Salud Carlos III-
European Union FEDER funds (PI 12/615). 
REFERENCES 
[1] Friedenstein, A.J.; Chailakhjan, R.K.; Lalykina, K.S. The develop-
ment of fibroblast colonies in monolayer cultures of guinea-pig 
bone marrow and spleen cells. Cell Tissue Kinet., 1970, 3, 393-403. 
[2] Alison, M.; Sarraf, C. Hepatic stem cells. J. Hepatol., 1998, 29, 
676-682. 
[3] Conrad, S.; Renninger, M.; Hennenlotter, J.; Wiesner, T.; Just, L.; 
Bonin, M.; Aicher, W.; Buhring, H.J.; Mattheus, U.; Mack, A.; 
Wagner, H.J.; Minger, S.; Matzkies, M.; Reppel, M.; Hescheler, J.; 
Sievert, K.D.; Stenzl, A.; Skutella, T. Generation of pluripotent 
stem cells from adult human testis. Nature, 2008, 456, 344-349. 
[4] Margolis, J.; Spradling, A. Identification and behavior of epithelial 
stem cells in the Drosophila ovary. Development, 1995, 121, 3797-
3807. 
[5] Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Doug-
las, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; 
Marshak, D.R. Multilineage potential of adult human mesenchymal 
stem cells. Science, 1999, 284, 143-147. 
[6] Potten, C.S. Stem cells in gastrointestinal epithelium: numbers, 
characteristics and death. Philos. Trans. R. Soc. Lond B. Biol. Sci., 
1998, 353, 821-830. 
[7] Weissman, I.L. Translating stem and progenitor cell biology to the 
clinic: barriers and opportunities. Science, 2000, 287, 1442-1446. 
[8] Peiffer, I.; Eid, P.; Barbet, R.; Li, M.L.; Oostendorp, R.A.; Hay-
dont, V.; Monier, M.N.; Milon, L.; Fortunel, N.; Charbord, P.; 
Tovey, M.; Hatzfeld, J.; Hatzfeld, A. A sub-population of high pro-
liferative potential-quiescent human mesenchymal stem cells is un-
der the reversible control of interferon alpha/beta. Leukemia, 2007, 
21, 714-724. 
[9] Anjos-Afonso, F.; Siapati, E.K.; Bonnet, D. In vivo contribution of 
murine mesenchymal stem cells into multiple cell-types under 
minimal damage conditions. J. Cell Sci., 2004, 117, 5655-5664. 
[10] Hsiao, S.H.; Lee, K.D.; Hsu, C.C.; Tseng, M.J.; Jin, V.X.; Sun, 
W.S.; Hung, Y.C.; Yeh, K.T.; Yan, P.S.; Lai, Y.Y.; Sun, H.S.; Lu, 
Y.J.; Chang, Y.S.; Tsai, S.J.; Huang, T.H.; Leu, Y.W. DNA methy-
lation of the Trip10 promoter accelerates mesenchymal stem cell 
lineage determination. Biochem. Biophys. Res. Commun., 2010, 
400, 305-312. 
[11] Koc, O.N.; Lazarus, H.M. Mesenchymal stem cells: heading into 
the clinic. Bone Marrow Transplant, 2001, 27, 235-239. 
[12] Lee, K.D.; Kuo, T.K.; Whang-Peng, J.; Chung, Y.F.; Lin, C.T.; 
Chou, S.H.; Chen, J.R.; Chen, Y.P.; Lee, O.K. In vitro hepatic dif-
ferentiation of human mesenchymal stem cells. Hepatology, 2004, 
40, 1275-1284. 
[13] Lee, O.K.; Kuo, T.K.; Chen, W.M.; Lee, K.D.; Hsieh, S.L.; Chen, 
T.H. Isolation of multipotent mesenchymal stem cells from umbili-
cal cord blood. Blood, 2004, 103, 1669-1675. 
380    Current Genomics, 2015, Vol. 16, No. 6 Pérez-Campo and Riancho 
[14] Halvorsen, Y.D.; Bond, A.; Sen, A.; Franklin, D.M.; Lea-Currie, 
Y.R.; Sujkowski, D.; Ellis, P.N.; Wilkison, W.O.; Gimble, J.M. 
Thiazolidinediones and glucocorticoids synergistically induce dif-
ferentiation of human adipose tissue stromal cells: biochemical, 
cellular, and molecular analysis. Metabolism, 2001, 50, 407-413. 
[15] Zuk, P.A.; Zhu, M.; Mizuno, H.; Huang, J.; Futrell, J.W.; Katz, 
A.J.; Benhaim, P.; Lorenz, H.P.; Hedrick, M.H. Multilineage cells 
from human adipose tissue: implications for cell-based therapies. 
Tissue Eng., 2001, 7, 211-228. 
[16] Erickson, G.R.; Gimble, J.M.; Franklin, D.M.; Rice, H.E.; Awad, 
H.; Guilak, F. Chondrogenic potential of adipose tissue-derived 
stromal cells in vitro and in vivo. Biochem. Biophys. Res. Commun., 
2002, 290, 763-769. 
[17] Kern, S.; Eichler, H.; Stoeve, J.; Kluter, H.; Bieback, K. Compara-
tive analysis of mesenchymal stem cells from bone marrow, um-
bilical cord blood, or adipose tissue. Stem Cells, 2006, 24, 1294-
1301. 
[18] Kolf, C.M.; Cho, E.; Tuan, R.S. Mesenchymal stromal cells. Biol-
ogy of adult mesenchymal stem cells: regulation of niche, self-
renewal and differentiation. Arthritis. Res. Ther., 2007, 9, 204. 
[19] Phinney, D.G.; Prockop, D.J. Concise review: mesenchymal 
stem/multipotent stromal cells: the state of transdifferentiation and 
modes of tissue repair--current views. Stem Cells, 2007, 25, 2896-
2902. 
[20] Tolar, J.; Nauta, A.J.; Osborn, M.J.; Panoskaltsis Mortari, A.; 
McElmurry, R.T.; Bell, S.; Xia, L.; Zhou, N.; Riddle, M.; Schroe-
der, T.M.; Westendorf, J.J.; McIvor, R.S.; Hogendoorn, P.C.; Szu-
hai, K.; Oseth, L.; Hirsch, B.; Yant, S.R.; Kay, M.A.; Peister, A.; 
Prockop, D.J.; Fibbe, W.E.; Blazar, B.R. Sarcoma derived from 
cultured mesenchymal stem cells. Stem Cells, 2007, 25, 371-379. 
[21] Kouzarides, T. Chromatin modifications and their function. Cell, 
2007, 128, 693-705. 
[22] Jaenisch, R.; Bird, A. Epigenetic regulation of gene expression: 
how the genome integrates intrinsic and environmental signals. Nat 
Genet, 2003, 33 Suppl, 245-254. 
[23] Vaissiere, T.; Sawan, C.; Herceg, Z. Epigenetic interplay between 
histone modifications and DNA methylation in gene silencing. Mu-
tat Res., 2008, 659, 40-48. 
[24] Bibikova, M.; Chudin, E.; Wu, B.; Zhou, L.; Garcia, E.W.; Liu, Y.; 
Shin, S.; Plaia, T.W.; Auerbach, J.M.; Arking, D.E.; Gonzalez, R.; 
Crook, J.; Davidson, B.; Schulz, T.C.; Robins, A.; Khanna, A.; Sar-
tipy, P.; Hyllner, J.; Vanguri, P.; Savant-Bhonsale, S.; Smith, A.K.; 
Chakravarti, A.; Maitra, A.; Rao, M.; Barker, D.L.; Loring, J.F.; 
Fan, J.B. Human embryonic stem cells have a unique epigenetic 
signature. Genome Res., 2006, 16, 1075-1083. 
[25] Calvanese, V.; Horrillo, A.; Hmadcha, A.; Suarez-Alvarez, B.; 
Fernandez, A.F.; Lara, E.; Casado, S.; Menendez, P.; Bueno, C.; 
Garcia-Castro, J.; Rubio, R.; Lapunzina, P.; Alaminos, M.; 
Borghese, L.; Terstegge, S.; Harrison, N.J.; Moore, H.D.; Brustle, 
O.; Lopez-Larrea, C.; Andrews, P.W.; Soria, B.; Esteller, M.; 
Fraga, M.F. Cancer genes hypermethylated in human embryonic 
stem cells. PLoS One, 2008, 3, e3294. 
[26] Mohn, F.; Weber, M.; Rebhan, M.; Roloff, T.C.; Richter, J.; 
Stadler, M.B.; Bibel, M.; Schubeler, D. Lineage-specific polycomb 
targets and de novo DNA methylation define restriction and poten-
tial of neuronal progenitors. Mol. Cell, 2008, 30, 755-766. 
[27] Qiu, J. Epigenetics: unfinished symphony. Nature, 2006, 441, 143-
145. 
[28] Vincent, A.; Van Seuningen, I. Epigenetics, stem cells and epithe-
lial cell fate. Differentiation, 2009, 78, 99-107. 
[29] Cho, Y.D.; Yoon, W.J.; Kim, W.J.; Woo, K.M.; Baek, J.H.; Lee, 
G.; Ku, Y.; van Wijnen, A.J.; Ryoo, H.M. Epigenetic modifications 
and canonical wingless/int-1 class (WNT) signaling enable trans-
differentiation of nonosteogenic cells into osteoblasts. J. Biol. 
Chem., 2014, 289, 20120-20128. 
[30] Wagner, E.R.; Luther, G.; Zhu, G.; Luo, Q.; Shi, Q.; Kim, S.H.; 
Gao, J.L.; Huang, E.; Gao, Y.; Yang, K.; Wang, L.; Teven, C.; Luo, 
X.; Liu, X.; Li, M.; Hu, N.; Su, Y.; Bi, Y.; He, B.C.; Tang, N.; Luo, 
J.; Chen, L.; Zuo, G.; Rames, R.; Haydon, R.C.; Luu, H.H.; He, 
T.C. Defective osteogenic differentiation in the development of os-
teosarcoma. Sarcoma, 2011, 2011, 325238. 
[31] Kanis, J.A.; Johnell, O.; Oden, A.; Sembo, I.; Redlund-Johnell, I.; 
Dawson, A.; De Laet, C.; Jonsson, B. Long-term risk of osteo-
porotic fracture in Malmo. Osteoporos Int, 2000, 11, 669-674. 
[32] Melton, L.J., 3rd; Atkinson, E.J.; O'Connor, M.K.; O'Fallon, W.M.; 
Riggs, B.L. Bone density and fracture risk in men. J Bone Miner 
Res, 1998, 13, 1915-1923. 
[33] Melton, L.J., 3rd; Chrischilles, E.A.; Cooper, C.; Lane, A.W.; 
Riggs, B.L. Perspective. How many women have osteoporosis? J 
Bone Miner. Res., 1992, 7, 1005-1010. 
[34] Misof, B.M.; Gamsjaeger, S.; Cohen, A.; Hofstetter, B.; Roschger, 
P.; Stein, E.; Nickolas, T.L.; Rogers, H.F.; Dempster, D.; Zhou, H.; 
Recker, R.; Lappe, J.; McMahon, D.; Paschalis, E.P.; Fratzl, P.; 
Shane, E.; Klaushofer, K. Bone material properties in premeno-
pausal women with idiopathic osteoporosis. J. Bone Miner. Res., 
2012, 27, 2551-2561. 
[35] Jilka, R.L. Biology of the basic multicellular unit and the patho-
physiology of osteoporosis. Med. Pediatr. Oncol., 2003, 41, 182-
185. 
[36] Kousteni, S.; Bellido, T.; Plotkin, L.I.; O'Brien, C.A.; Bodenner, 
D.L.; Han, L.; Han, K.; DiGregorio, G.B.; Katzenellenbogen, J.A.; 
Katzenellenbogen, B.S.; Roberson, P.K.; Weinstein, R.S.; Jilka, 
R.L.; Manolagas, S.C. Nongenotropic, sex-nonspecific signaling 
through the estrogen or androgen receptors: dissociation from tran-
scriptional activity. Cell, 2001, 104, 719-730. 
[37] Kawai, M.; Rosen, C.J. PPARgamma: a circadian transcription 
factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol., 
2010, 6, 629-636. 
[38] McCauley, L.K. c-Maf and you won't see fat. J. Clin. Invest., 2010, 
120, 3440-3442. 
[39] Addison, W.N.; Fu, M.M.; Yang, H.X.; Lin, Z.; Nagano, K.; Gori, 
F.; Baron, R. Direct transcriptional repression of Zfp423 by Zfp521 
mediates a bone morphogenic protein-dependent osteoblast versus 
adipocyte lineage commitment switch. Mol Cell Biol, 2014, 34, 
3076-3085. 
[40] Hakelien, A.M.; Bryne, J.C.; Harstad, K.G.; Lorenz, S.; Paulsen, J.; 
Sun, J.; Mikkelsen, T.S.; Myklebost, O.; Meza-Zepeda, L.A. The 
regulatory landscape of osteogenic differentiation. Stem Cells, 
2014, 32, 2780-2793. 
[41] Qi, H.; Aguiar, D.J.; Williams, S.M.; La Pean, A.; Pan, W.; Ver-
faillie, C.M. Identification of genes responsible for osteoblast dif-
ferentiation from human mesodermal progenitor cells. Proc. Natl. 
Acad. Sci. U S A, 2003, 100, 3305-3310. 
[42] Kulterer, B.; Friedl, G.; Jandrositz, A.; Sanchez-Cabo, F.; 
Prokesch, A.; Paar, C.; Scheideler, M.; Windhager, R.; Preisegger, 
K.H.; Trajanoski, Z. Gene expression profiling of human mesen-
chymal stem cells derived from bone marrow during expansion and 
osteoblast differentiation. BMC Genomics, 2007, 8, 70. 
[43] Sorensen, A.L.; Jacobsen, B.M.; Reiner, A.H.; Andersen, I.S.; 
Collas, P. Promoter DNA methylation patterns of differentiated 
cells are largely programmed at the progenitor stage. Mol. Biol. 
Cell, 2010, 21, 2066-2077. 
[44] Gibney, E.R.; Nolan, C.M. Epigenetics and gene expression. He-
redity (Edinb), 2010, 105, 4-13. 
[45] Portela, A.; Esteller, M. Epigenetic modifications and human dis-
ease. Nat. Biotechnol., 2010, 28, 1057-1068. 
[46] Agger, K.; Christensen, J.; Cloos, P.A.; Helin, K. The emerging 
functions of histone demethylases. Curr. Opin. Genet. Dev., 2008, 
18, 159-168. 
[47] Shi, Y.; Whetstine, J.R. Dynamic regulation of histone lysine meth-
ylation by demethylases. Mol. Cell., 2007, 25, 1-14. 
[48] Asp, P.; Blum, R.; Vethantham, V.; Parisi, F.; Micsinai, M.; Cheng, 
J.; Bowman, C.; Kluger, Y.; Dynlacht, B.D. Genome-wide remod-
eling of the epigenetic landscape during myogenic differentiation. 
Proc. Natl. Acad. Sci. U S A, 2011, 108, E149-158. 
[49] Hsieh, J.; Nakashima, K.; Kuwabara, T.; Mejia, E.; Gage, F.H. 
Histone deacetylase inhibition-mediated neuronal differentiation of 
multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. U S 
A, 2004, 101, 16659-16664. 
[50] Takanashi, M.; Oikawa, K.; Fujita, K.; Kudo, M.; Kinoshita, M.; 
Kuroda, M. Heterochromatin protein 1gamma epigenetically regu-
lates cell differentiation and exhibits potential as a therapeutic tar-
get for various types of cancers. Am. J. Pathol., 2009, 174, 309-
316. 
[51] Lee, S.; Park, J.R.; Seo, M.S.; Roh, K.H.; Park, S.B.; Hwang, J.W.; 
Sun, B.; Seo, K.; Lee, Y.S.; Kang, S.K.; Jung, J.W.; Kang, K.S. 
Histone deacetylase inhibitors decrease proliferation potential and 
multilineage differentiation capability of human mesenchymal stem 
cells. Cell Prolif., 2009, 42, 711-720. 
[52] de Boer, J.; Licht, R.; Bongers, M.; van der Klundert, T.; Arends, 
R.; van Blitterswijk, C. Inhibition of histone acetylation as a tool in 
bone tissue engineering. Tissue Eng., 2006, 12, 2927-2937. 
Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation Current Genomics, 2015, Vol. 16, No. 6    381 
[53] Cho, H.H.; Park, H.T.; Kim, Y.J.; Bae, Y.C.; Suh, K.T.; Jung, J.S. 
Induction of osteogenic differentiation of human mesenchymal 
stem cells by histone deacetylase inhibitors. J. Cell Biochem., 2005, 
96, 533-542. 
[54] Schroeder, T.M.; Nair, A.K.; Staggs, R.; Lamblin, A.F.; 
Westendorf, J.J. Gene profile analysis of osteoblast genes differen-
tially regulated by histone deacetylase inhibitors. BMC Genomics, 
2007, 8, 362. 
[55] Schroeder, T.M.; Westendorf, J.J. Histone deacetylase inhibitors 
promote osteoblast maturation. J. Bone Miner. Res., 2005, 20, 
2254-2263. 
[56] Hu, X.; Zhang, X.; Dai, L.; Zhu, J.; Jia, Z.; Wang, W.; Zhou, C.; 
Ao, Y. Histone deacetylase inhibitor trichostatin A promotes the 
osteogenic differentiation of rat adipose-derived stem cells by alter-
ing the epigenetic modifications on Runx2 promoter in a BMP sig-
naling-dependent manner. Stem Cells Dev., 2013, 22, 248-255. 
[57] Nissen-Meyer, L.S.; Svalheim, S.; Tauboll, E.; Reppe, S.; Lekva, 
T.; Solberg, L.B.; Melhus, G.; Reinholt, F.P.; Gjerstad, L.; 
Jemtland, R. Levetiracetam, phenytoin, and valproate act differ-
ently on rat bone mass, structure, and metabolism. Epilepsia, 2007, 
48, 1850-1860. 
[58] Senn, S.M.; Kantor, S.; Poulton, I.J.; Morris, M.J.; Sims, N.A.; 
O'Brien, T.J.; Wark, J.D. Adverse effects of valproate on bone: de-
fining a model to investigate the pathophysiology. Epilepsia, 2010, 
51, 984-993. 
[59] McGee-Lawrence, M.E.; Westendorf, J.J. Histone deacetylases in 
skeletal development and bone mass maintenance. Gene, 2011, 
474, 1-11. 
[60] Di Bernardo, G.; Squillaro, T.; Dell'Aversana, C.; Miceli, M.; 
Cipollaro, M.; Cascino, A.; Altucci, L.; Galderisi, U. Histone 
deacetylase inhibitors promote apoptosis and senescence in human 
mesenchymal stem cells. Stem Cells Dev., 2009, 18, 573-581. 
[61] Vega, R.B.; Matsuda, K.; Oh, J.; Barbosa, A.C.; Yang, X.; Mead-
ows, E.; McAnally, J.; Pomajzl, C.; Shelton, J.M.; Richardson, 
J.A.; Karsenty, G.; Olson, E.N. Histone deacetylase 4 controls 
chondrocyte hypertrophy during skeletogenesis. Cell, 2004, 119, 
555-566. 
[62] Razidlo, D.F.; Whitney, T.J.; Casper, M.E.; McGee-Lawrence, 
M.E.; Stensgard, B.A.; Li, X.; Secreto, F.J.; Knutson, S.K.; Hie-
bert, S.W.; Westendorf, J.J. Histone deacetylase 3 depletion in os-
teo/chondroprogenitor cells decreases bone density and increases 
marrow fat. PLoS One, 2010, 5, e11492. 
[63] Choo, M.K.; Yeo, H.; Zayzafoon, M. NFATc1 mediates HDAC-
dependent transcriptional repression of osteocalcin expression dur-
ing osteoblast differentiation. Bone, 2009, 45, 579-589. 
[64] Iwami, K.; Moriyama, T. Effects of short chain fatty acid, sodium 
butyrate, on osteoblastic cells and osteoclastic cells. Int. J. Bio-
chem., 1993, 25, 1631-1635. 
[65] Lee, H.W.; Suh, J.H.; Kim, A.Y.; Lee, Y.S.; Park, S.Y.; Kim, 
J.B. Histone deacetylase 1-mediated histone modification regu-
lates osteoblast differentiation. Mol. Endocrinol., 2006, 20, 2432-
2443. 
[66] Bhaskara, S.; Chyla, B.J.; Amann, J.M.; Knutson, S.K.; Cortez, D.; 
Sun, Z.W.; Hiebert, S.W. Deletion of histone deacetylase 3 reveals 
critical roles in S phase progression and DNA damage control. Mol. 
Cell, 2008, 30, 61-72. 
[67] Kim, S.H.; Lee, J.W.; Choi, K.G.; Chung, H.W.; Lee, H.W. A 6-
month longitudinal study of bone mineral density with antiepileptic 
drug monotherapy. Epilepsy Behav, 2007, 10, 291-295. 
[68] Sato, Y.; Kondo, I.; Ishida, S.; Motooka, H.; Takayama, K.; To-
mita, Y.; Maeda, H.; Satoh, K. Decreased bone mass and increased 
bone turnover with valproate therapy in adults with epilepsy. Neu-
rology, 2001, 57, 445-449. 
[69] Tsukahara, H.; Kimura, K.; Todoroki, Y.; Ohshima, Y.; Hiraoka, 
M.; Shigematsu, Y.; Tsukahara, Y.; Miura, M.; Mayumi, M. Bone 
mineral status in ambulatory pediatric patients on long-term anti-
epileptic drug therapy. Pediatr. Int., 2002, 44, 247-253. 
[70] Cohen-Kfir, E.; Artsi, H.; Levin, A.; Abramowitz, E.; Bajayo, A.; 
Gurt, I.; Zhong, L.; D'Urso, A.; Toiber, D.; Mostoslavsky, R.; 
Dresner-Pollak, R. Sirt1 is a regulator of bone mass and a repressor 
of Sost encoding for sclerostin, a bone formation inhibitor. Endo-
crinology, 2011, 152, 4514-4524. 
[71] Shen, J.; Hovhannisyan, H.; Lian, J.B.; Montecino, M.A.; Stein, 
G.S.; Stein, J.L.; Van Wijnen, A.J. Transcriptional induction of the 
osteocalcin gene during osteoblast differentiation involves acetyla-
tion of histones h3 and h4. Mol. Endocrinol., 2003, 17, 743-756. 
[72] Sierra, J.; Villagra, A.; Paredes, R.; Cruzat, F.; Gutierrez, S.; Javed, 
A.; Arriagada, G.; Olate, J.; Imschenetzky, M.; Van Wijnen, A.J.; 
Lian, J.B.; Stein, G.S.; Stein, J.L.; Montecino, M. Regulation of the 
bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and 
the vitamin D3 receptor but not p300 intrinsic histone acetyltrans-
ferase activity. Mol. Cell Biol., 2003, 23, 3339-3351. 
[73] Bird, A.P.; Wolffe, A.P. Methylation-induced repression--belts, 
braces, and chromatin. Cell, 1999, 99, 451-454. 
[74] Villagra, A.; Gutierrez, J.; Paredes, R.; Sierra, J.; Puchi, M.; Im-
schenetzky, M.; Wijnen Av, A.; Lian, J.; Stein, G.; Stein, J.; Mon-
tecino, M. Reduced CpG methylation is associated with transcrip-
tional activation of the bone-specific rat osteocalcin gene in os-
teoblasts. J. Cell Biochem., 2002, 85, 112-122. 
[75] Paredes, R.; Gutierrez, J.; Gutierrez, S.; Allison, L.; Puchi, M.; 
Imschenetzky, M.; van Wijnen, A.; Lian, J.; Stein, G.; Stein, J.; 
Montecino, M. Interaction of the 1alpha,25-dihydroxyvitamin D3 
receptor at the distal promoter region of the bone-specific osteocal-
cin gene requires nucleosomal remodelling. Biochem J., 2002, 363, 
667-676. 
[76] Gutierrez, S.; Javed, A.; Tennant, D.K.; van Rees, M.; Montecino, 
M.; Stein, G.S.; Stein, J.L.; Lian, J.B. CCAAT/enhancer-binding 
proteins (C/EBP) beta and delta activate osteocalcin gene transcrip-
tion and synergize with Runx2 at the C/EBP element to regulate 
bone-specific expression. J. Biol Chem., 2002, 277, 1316-1323. 
[77] Javed, A.; Gutierrez, S.; Montecino, M.; van Wijnen, A.J.; Stein, 
J.L.; Stein, G.S.; Lian, J.B. Multiple Cbfa/AML sites in the rat os-
teocalcin promoter are required for basal and vitamin D-responsive 
transcription and contribute to chromatin organization. Mol. Cell. 
Biol., 1999, 19, 7491-7500. 
[78] Wang, C.Y.; Yang, S.F.; Wang, Z.; Tan, J.M.; Xing, S.M.; Chen, 
D.C.; Xu, S.M.; Yuan, W. PCAF acetylates Runx2 and promotes 
osteoblast differentiation. J. Bone Miner. Metab., 2013, 31, 381-
389. 
[79] Jeon, E.J.; Lee, K.Y.; Choi, N.S.; Lee, M.H.; Kim, H.N.; Jin, Y.H.; 
Ryoo, H.M.; Choi, J.Y.; Yoshida, M.; Nishino, N.; Oh, B.C.; Lee, 
K.S.; Lee, Y.H.; Bae, S.C. Bone morphogenetic protein-2 stimu-
lates Runx2 acetylation. J. Biol. Chem., 2006, 281, 16502-16511. 
[80] Pelletier, N.; Champagne, N.; Stifani, S.; Yang, X.J. MOZ and 
MORF histone acetyltransferases interact with the Runt-domain 
transcription factor Runx2. Oncogene, 2002, 21, 2729-2740. 
[81] Bernstein, B.E.; Mikkelsen, T.S.; Xie, X.; Kamal, M.; Huebert, 
D.J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; 
Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S.L.; Lander, E.S. 
A bivalent chromatin structure marks key developmental genes in 
embryonic stem cells. Cell, 2006, 125, 315-326. 
[82] Wei, Y.; Chen, Y.H.; Li, L.Y.; Lang, J.; Yeh, S.P.; Shi, B.; Yang, 
C.C.; Yang, J.Y.; Lin, C.Y.; Lai, C.C.; Hung, M.C. CDK1-
dependent phosphorylation of EZH2 suppresses methylation of 
H3K27 and promotes osteogenic differentiation of human mesen-
chymal stem cells. Nat. Cell Biol., 2011, 13, 87-94. 
[83] Van Hoof, D.; Munoz, J.; Braam, S.R.; Pinkse, M.W.; Linding, R.; 
Heck, A.J.; Mummery, C.L.; Krijgsveld, J. Phosphorylation dy-
namics during early differentiation of human embryonic stem cells. 
Cell Stem Cell, 2009, 5, 214-226. 
[84] Schwarz, D.; Varum, S.; Zemke, M.; Scholer, A.; Baggiolini, A.; 
Draganova, K.; Koseki, H.; Schubeler, D.; Sommer, L. Ezh2 is re-
quired for neural crest-derived cartilage and bone formation. De-
velopment, 2014, 141, 867-877. 
[85] Nayak, A.; Viale-Bouroncle, S.; Morsczeck, C.; Muller, S. The 
SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 meth-
yltransferase complexes and controls osteogenic differentiation. 
Mol. Cell., 2014, 55, 47-58. 
[86] Ye, L.; Fan, Z.; Yu, B.; Chang, J.; Al Hezaimi, K.; Zhou, X.; Park, 
N.H.; Wang, C.Y. Histone demethylases KDM4B and KDM6B 
promotes osteogenic differentiation of human MSCs. Cell Stem 
Cell, 2012, 11, 50-61. 
[87] Lan, F.; Bayliss, P.E.; Rinn, J.L.; Whetstine, J.R.; Wang, J.K.; 
Chen, S.; Iwase, S.; Alpatov, R.; Issaeva, I.; Canaani, E.; Roberts, 
T.M.; Chang, H.Y.; Shi, Y. A histone H3 lysine 27 demethylase 
regulates animal posterior development. Nature, 2007, 449, 689-
694. 
[88] Shi, Y. Histone lysine demethylases: emerging roles in develop-
ment, physiology and disease. Nat Rev Genet, 2007, 8, 829-833. 
[89] Fan, Z.; Yamaza, T.; Lee, J.S.; Yu, J.; Wang, S.; Fan, G.; Shi, S.; 
Wang, C.Y. BCOR regulates mesenchymal stem cell function by 
epigenetic mechanisms. Nat Cell Biol., 2009, 11, 1002-1009. 
382    Current Genomics, 2015, Vol. 16, No. 6 Pérez-Campo and Riancho 
[90] Huynh, K.D.; Fischle, W.; Verdin, E.; Bardwell, V.J. BCoR, a 
novel corepressor involved in BCL-6 repression. Genes Dev, 2000, 
14, 1810-1823. 
[91] Gearhart, M.D.; Corcoran, C.M.; Wamstad, J.A.; Bardwell, V.J. 
Polycomb group and SCF ubiquitin ligases are found in a novel 
BCOR complex that is recruited to BCL6 targets. Mol. Cell Biol., 
2006, 26, 6880-6889. 
[92] Sanchez, C.; Sanchez, I.; Demmers, J.A.; Rodriguez, P.; Stroub-
oulis, J.; Vidal, M. Proteomics analysis of Ring1B/Rnf2 interactors 
identifies a novel complex with the Fbxl10/Jhdm1B histone de-
methylase and the Bcl6 interacting corepressor. Mol. Cell Pro-
teomics, 2007, 6, 820-834. 
[93] Brewer, S.; Feng, W.; Huang, J.; Sullivan, S.; Williams, T. Wnt1-
Cre-mediated deletion of AP-2alpha causes multiple neural crest-
related defects. Dev. Biol., 2004, 267, 135-152. 
[94] Schorle, H.; Meier, P.; Buchert, M.; Jaenisch, R.; Mitchell, P.J. 
Transcription factor AP-2 essential for cranial closure and cranio-
facial development. Nature, 1996, 381, 235-238. 
[95] Fodor, B.D.; Kubicek, S.; Yonezawa, M.; O'Sullivan, R.J.; Sen-
gupta, R.; Perez-Burgos, L.; Opravil, S.; Mechtler, K.; Schotta, G.; 
Jenuwein, T. Jmjd2b antagonizes H3K9 trimethylation at pericen-
tric heterochromatin in mammalian cells. Genes Dev., 2006, 20, 
1557-1562. 
[96] Xu, J.; Yu, B.; Hong, C.; Wang, C.Y. KDM6B epigenetically regu-
lates odontogenic differentiation of dental mesenchymal stem cells. 
Int. J. Oral Sci., 2013, 5, 200-205. 
[97] Gimble, F.S.; Stephens, B.W. Substitutions in conserved dode-
capeptide motifs that uncouple the DNA binding and DNA cleav-
age activities of PI-SceI endonuclease. J. Biol. Chem., 1995, 270, 
5849-5856. 
[98] Hata, K.; Nishimura, R.; Ikeda, F.; Yamashita, K.; Matsubara, T.; 
Nokubi, T.; Yoneda, T. Differential roles of Smad1 and p38 kinase 
in regulation of peroxisome proliferator-activating receptor gamma 
during bone morphogenetic protein 2-induced adipogenesis. Mol. 
Biol. Cell., 2003, 14, 545-555. 
[99] Huang, H.; Song, T.J.; Li, X.; Hu, L.; He, Q.; Liu, M.; Lane, M.D.; 
Tang, Q.Q. BMP signaling pathway is required for commitment of 
C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc. 
Natl. Acad. Sci. U S A, 2009, 106, 12670-12675. 
[100] Jin, W.; Takagi, T.; Kanesashi, S.N.; Kurahashi, T.; Nomura, T.; 
Harada, J.; Ishii, S. Schnurri-2 controls BMP-dependent adipo-
genesis via interaction with Smad proteins. Dev Cell, 2006, 10, 
461-471. 
[101] Tseng, Y.H.; Kokkotou, E.; Schulz, T.J.; Huang, T.L.; Winnay, 
J.N.; Taniguchi, C.M.; Tran, T.T.; Suzuki, R.; Espinoza, D.O.; 
Yamamoto, Y.; Ahrens, M.J.; Dudley, A.T.; Norris, A.W.; Kul-
karni, R.N.; Kahn, C.R. New role of bone morphogenetic protein 7 
in brown adipogenesis and energy expenditure. Nature, 2008, 454, 
1000-1004. 
[102] Gupta, R.K.; Arany, Z.; Seale, P.; Mepani, R.J.; Ye, L.; Conroe, 
H.M.; Roby, Y.A.; Kulaga, H.; Reed, R.R.; Spiegelman, B.M. 
Transcriptional control of preadipocyte determination by Zfp423. 
Nature, 2010, 464, 619-623. 
[103] Wang, L.; Xu, S.; Lee, J.E.; Baldridge, A.; Grullon, S.; Peng, W.; 
Ge, K. Histone H3K9 methyltransferase G9a represses PPAR-
gamma expression and adipogenesis. EMBO J., 2013, 32, 45-59. 
[104] Klose, R.J.; Bird, A.P. Genomic DNA methylation: the mark and 
its mediators. Trends Biochem. Sci., 2006, 31, 89-97. 
[105] Weber, M.; Hellmann, I.; Stadler, M.B.; Ramos, L.; Paabo, S.; 
Rebhan, M.; Schubeler, D. Distribution, silencing potential and 
evolutionary impact of promoter DNA methylation in the human 
genome. Nat. Genet., 2007, 39, 457-466. 
[106] Ben-Porath, I.; Cedar, H. Epigenetic crosstalk. Mol. Cell, 2001, 8, 
933-935. 
[107] Richards, E.J.; Elgin, S.C. Epigenetic codes for heterochromatin 
formation and silencing: rounding up the usual suspects. Cell, 
2002, 108, 489-500. 
[108] Jones, P.L.; Veenstra, G.J.; Wade, P.A.; Vermaak, D.; Kass, S.U.; 
Landsberger, N.; Strouboulis, J.; Wolffe, A.P. Methylated DNA 
and MeCP2 recruit histone deacetylase to repress transcription. 
Nat. Genet., 1998, 19, 187-191. 
[109] Mutskov, V.; Felsenfeld, G. Silencing of transgene transcription 
precedes methylation of promoter DNA and histone H3 lysine 9. 
EMBO J., 2004, 23, 138-149. 
[110] Borgel, J.; Guibert, S.; Li, Y.; Chiba, H.; Schubeler, D.; Sasaki, H.; 
Forne, T.; Weber, M. Targets and dynamics of promoter DNA 
methylation during early mouse development. Nat. Genet., 2010, 
42, 1093-1100. 
[111] Huang, K.; Wu, Z.; Liu, Z.; Hu, G.; Yu, J.; Chang, K.H.; Kim, 
K.P.; Le, T.; Faull, K.F.; Rao, N.; Gennery, A.; Xue, Z.; Wang, 
C.Y.; Pellegrini, M.; Fan, G. Selective demethylation and altered 
gene expression are associated with ICF syndrome in human-
induced pluripotent stem cells and mesenchymal stem cells. Hum. 
Mol. Genet., 2014, 23, 6448-6457. 
[112] Biniszkiewicz, D.; Gribnau, J.; Ramsahoye, B.; Gaudet, F.; Eggan, 
K.; Humpherys, D.; Mastrangelo, M.A.; Jun, Z.; Walter, J.; 
Jaenisch, R. Dnmt1 overexpression causes genomic hypermethyla-
tion, loss of imprinting, and embryonic lethality. Mol. Cell Biol., 
2002, 22, 2124-2135. 
[113] Chan, M.F.; van Amerongen, R.; Nijjar, T.; Cuppen, E.; Jones, 
P.A.; Laird, P.W. Reduced rates of gene loss, gene silencing, and 
gene mutation in Dnmt1-deficient embryonic stem cells. Mol. Cell 
Biol., 2001, 21, 7587-7600. 
[114] Jackson-Grusby, L.; Beard, C.; Possemato, R.; Tudor, M.; Fam-
brough, D.; Csankovszki, G.; Dausman, J.; Lee, P.; Wilson, C.; 
Lander, E.; Jaenisch, R. Loss of genomic methylation causes p53-
dependent apoptosis and epigenetic deregulation. Nat. Genet., 
2001, 27, 31-39. 
[115] Rhee, I.; Jair, K.W.; Yen, R.W.; Lengauer, C.; Herman, J.G.; Kin-
zler, K.W.; Vogelstein, B.; Baylin, S.B.; Schuebel, K.E. CpG meth-
ylation is maintained in human cancer cells lacking DNMT1. 
Nature, 2000, 404, 1003-1007. 
[116] Tsai, C.C.; Su, P.F.; Huang, Y.F.; Yew, T.L.; Hung, S.C. Oct4 and 
Nanog directly regulate Dnmt1 to maintain self-renewal and 
undifferentiated state in mesenchymal stem cells. Mol. Cell., 2012, 
47, 169-182. 
[117] Collas, P. Programming differentiation potential in mesenchymal 
stem cells. Epigenetics, 2010, 5, 476-482. 
[118] Boquest, A.C.; Noer, A.; Sorensen, A.L.; Vekterud, K.; Collas, P. 
CpG methylation profiles of endothelial cell-specific gene pro-
moter regions in adipose tissue stem cells suggest limited differen-
tiation potential toward the endothelial cell lineage. Stem Cells, 
2007, 25, 852-861. 
[119] Sorensen, A.L.; Timoskainen, S.; West, F.D.; Vekterud, K.; Bo-
quest, A.C.; Ahrlund-Richter, L.; Stice, S.L.; Collas, P. Lineage-
specific promoter DNA methylation patterns segregate adult pro-
genitor cell types. Stem Cells Dev., 2010, 19, 1257-1266. 
[120] Juttermann, R.; Li, E.; Jaenisch, R. Toxicity of 5-aza-2'-
deoxycytidine to mammalian cells is mediated primarily by cova-
lent trapping of DNA methyltransferase rather than DNA demethy-
lation. Proc. Natl. Acad. Sci. U S A, 1994, 91, 11797-11801. 
[121] El-Serafi, A.T.; Oreffo, R.O.; Roach, H.I. Epigenetic modifiers 
influence lineage commitment of human bone marrow stromal 
cells: Differential effects of 5-aza-deoxycytidine and trichostatin A. 
Differentiation, 2011, 81, 35-41. 
[122] Yan, X.; Ehnert, S.; Culmes, M.; Bachmann, A.; Seeliger, C.; 
Schyschka, L.; Wang, Z.; Rahmanian-Schwarz, A.; Stockle, U.; De 
Sousa, P.A.; Pelisek, J.; Nussler, A.K. 5-azacytidine improves the 
osteogenic differentiation potential of aged human adipose-derived 
mesenchymal stem cells by DNA demethylation. PLoS One, 2014, 
9, e90846. 
[123] Zhu, X.W.; Zuo, J.L.; Liu, Y.H.; Zang, R.; Li, Y.K.; Wang, X.; Li, 
J.M. Osteogenesis of umbilical mesenchymal stem cells is en-
hanced in absence of DNA methyltransferase 3B (DNMT3B) 
through upregulating Runx2 expression. Eur. Rev. Med. Pharma-
col. Sci, 2014, 18, 3004-3009. 
[124] Fouse, S.D.; Shen, Y.; Pellegrini, M.; Cole, S.; Meissner, A.; Van 
Neste, L.; Jaenisch, R.; Fan, G. Promoter CpG methylation con-
tributes to ES cell gene regulation in parallel with Oct4/Nanog, 
PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem 
Cell, 2008, 2, 160-169. 
[125] Lagarkova, M.A.; Volchkov, P.Y.; Lyakisheva, A.V.; Philonenko, 
E.S.; Kiselev, S.L. Diverse epigenetic profile of novel human em-
bryonic stem cell lines. Cell Cycle, 2006, 5, 416-420. 
[126] Berdasco, M.; Melguizo, C.; Prados, J.; Gomez, A.; Alaminos, M.; 
Pujana, M.A.; Lopez, M.; Setien, F.; Ortiz, R.; Zafra, I.; Aranega, 
A.; Esteller, M. DNA methylation plasticity of human adipose-
derived stem cells in lineage commitment. Am. J. Pathol., 2012, 
181, 2079-2093. 
[127] Aranda, P.; Agirre, X.; Ballestar, E.; Andreu, E.J.; Roman-Gomez, 
J.; Prieto, I.; Martin-Subero, J.I.; Cigudosa, J.C.; Siebert, R.; 
Esteller, M.; Prosper, F. Epigenetic signatures associated with dif-
Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation Current Genomics, 2015, Vol. 16, No. 6    383 
ferent levels of differentiation potential in human stem cells. PLoS 
One, 2009, 4, e7809. 
[128] Kang, M.I.; Kim, H.S.; Jung, Y.C.; Kim, Y.H.; Hong, S.J.; Kim, 
M.K.; Baek, K.H.; Kim, C.C.; Rhyu, M.G. Transitional CpG meth-
ylation between promoters and retroelements of tissue-specific 
genes during human mesenchymal cell differentiation. J. Cell Bio-
chem., 2007, 102, 224-239. 
[129] Lee, J.Y.; Lee, Y.M.; Kim, M.J.; Choi, J.Y.; Park, E.K.; Kim, S.Y.; 
Lee, S.P.; Yang, J.S.; Kim, D.S. Methylation of the mouse DIx5 
and Osx gene promoters regulates cell type-specific gene expres-
sion. Mol. Cells, 2006, 22, 182-188. 
[130] Zhang, R.P.; Shao, J.Z.; Xiang, L.X. GADD45A protein plays an 
essential role in active DNA demethylation during terminal os-
teogenic differentiation of adipose-derived mesenchymal stem 
cells. J. Biol. Chem., 2011, 286, 41083-41094. 
[131] Delgado-Calle, J.; Sanudo, C.; Bolado, A.; Fernandez, A.F.; Aro-
zamena, J.; Pascual-Carra, M.A.; Rodriguez-Rey, J.C.; Fraga, M.F.; 
Bonewald, L.; Riancho, J.A. DNA methylation contributes to the 
regulation of sclerostin expression in human osteocytes. J. Bone 
Miner. Res., 2012, 27, 926-937. 
[132] Delgado-Calle, J.; Sanudo, C.; Fernandez, A.F.; Garcia-Renedo, R.; 
Fraga, M.F.; Riancho, J.A. Role of DNA methylation in the regula-
tion of the RANKL-OPG system in human bone. Epigenetics, 
2012, 7, 83-91. 
[133] Delgado-Calle, J.; Sanudo, C.; Sanchez-Verde, L.; Garcia-Renedo, 
R.J.; Arozamena, J.; Riancho, J.A. Epigenetic regulation of alkaline 
phosphatase in human cells of the osteoblastic lineage. Bone, 2011, 
49, 830-838. 
[134] Zhou, G.S.; Zhang, X.L.; Wu, J.P.; Zhang, R.P.; Xiang, L.X.; Dai, 
L.C.; Shao, J.Z. 5-Azacytidine facilitates osteogenic gene expres-
sion and differentiation of mesenchymal stem cells by alteration in 
DNA methylation. Cytotechnology, 2009,  
[135] Bedford, M.T.; Richard, S. Arginine methylation an emerging 
regulator of protein function. Mol Cell, 2005, 18, 263-272. 
[136] Huang, J.; Berger, S.L. The emerging field of dynamic lysine 
methylation of non-histone proteins. Curr. Opin. Genet. Dev., 
2008, 18, 152-158. 
[137] Bartel, R.L.; Borchardt, R.T. Effects of adenosine dialdehyde on S-
adenosylhomocysteine hydrolase and S-adenosylmethionine-
dependent transmethylations in mouse L929 cells. Mol. Pharma-
col., 1984, 25, 418-424. 
[138] Hermes, M.; Osswald, H.; Mattar, J.; Kloor, D. Influence of an 
altered methylation potential on mRNA methylation and gene ex-
pression in HepG2 cells. Exp. Cell Res., 2004, 294, 325-334. 
[139] Fontecave, M.; Atta, M.; Mulliez, E. S-adenosylmethionine: noth-
ing goes to waste. Trends Biochem. Sci., 2004, 29, 243-249. 
[140] Vaes, B.L.; Lute, C.; van der Woning, S.P.; Piek, E.; Vermeer, J.; 
Blom, H.J.; Mathers, J.C.; Muller, M.; de Groot, L.C.; Steegenga, 
W.T. Inhibition of methylation decreases osteoblast differentiation 
via a non-DNA-dependent methylation mechanism. Bone, 2010, 
46, 514-523. 
[141] Schmitz, K.M.; Schmitt, N.; Hoffmann-Rohrer, U.; Schafer, A.; 
Grummt, I.; Mayer, C. TAF12 recruits Gadd45a and the nucleotide 
excision repair complex to the promoter of rRNA genes leading to 
active DNA demethylation. Mol. Cell, 2009, 33, 344-353. 
[142] Davis, C.D.; Ross, S.A. Dietary components impact histone modi-
fications and cancer risk. Nutr. Rev., 2007, 65, 88-94. 
[143] Chen, C.C.; Wang, K.Y.; Shen, C.K. DNA 5-methylcytosine de-
methylation activities of the mammalian DNA methyltransferases. 
J Biol Chem, 2013, 288, 9084-9091. 
[144] Haasper, C.; Jagodzinski, M.; Drescher, M.; Meller, R.; Wehmeier, 
M.; Krettek, C.; Hesse, E. Cyclic strain induces FosB and initiates 
osteogenic differentiation of mesenchymal cells. Exp. Toxicol. 
Pathol., 2008, 59, 355-363. 
[145] Haudenschild, A.K.; Hsieh, A.H.; Kapila, S.; Lotz, J.C. Pressure 
and distortion regulate human mesenchymal stem cell gene expres-
sion. Ann. Biomed. Eng., 2009, 37, 492-502. 
[146] Jagodzinski, M.; Breitbart, A.; Wehmeier, M.; Hesse, E.; Haasper, 
C.; Krettek, C.; Zeichen, J.; Hankemeier, S. Influence of perfusion 
and cyclic compression on proliferation and differentiation of bone 
marrow stromal cells in 3-dimensional culture. J. Biomech., 2008, 
41, 1885-1891. 
[147] Pelaez, D.; Arita, N.; Cheung, H.S. Extracellular signal-regulated 
kinase (ERK) dictates osteogenic and/or chondrogenic lineage 
commitment of mesenchymal stem cells under dynamic compres-
sion. Biochem. Biophys. Res. Commun., 2012, 417, 1286-1291. 
[148] Gurkan, U.A.; Akkus, O. The mechanical environment of bone 
marrow: a review. Ann Biomed Eng, 2008, 36, 1978-1991. 
[149] Li, Y.J.; Batra, N.N.; You, L.; Meier, S.C.; Coe, I.A.; Yellowley, 
C.E.; Jacobs, C.R. Oscillatory fluid flow affects human marrow 
stromal cell proliferation and differentiation. J. Orthop. Res., 2004, 
22, 1283-1289. 
[150] Arnsdorf, E.J.; Tummala, P.; Castillo, A.B.; Zhang, F.; Jacobs, 
C.R. The epigenetic mechanism of mechanically induced os-
teogenic differentiation. J. Biomech., 2010, 43, 2881-2886. 
[151] Li, Y.; Chu, J.S.; Kurpinski, K.; Li, X.; Bautista, D.M.; Yang, L.; 
Sung, K.L.; Li, S. Biophysical regulation of histone acetylation in 
mesenchymal stem cells. Biophys J., 2011, 100, 1902-1909. 
 
 
 
 
Received: March 15, 2015                                                                               Revised: March 27, 2015                                                                                    Accepted: April 07, 2015 
